Clinical Benefit of Topoisomerase Downregulation: A Phase I Pilot Study
The rationale to study the downregulation of topoisomerase enzyme in ovarian cancer in
relationship to the cell cycle distribution of the cancer cells after a prolonged continuous
exposure to topo I and II poisons is to better understand the relationship between cell
cycle and topo poisoning, which may lead to better clinical trial designs.
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the regulation of topoisomerase I and II following alternating prolonged exposure to topotecan and etoposide (VP-16)
3 years
Yes
Claire F Verschraegen, MD
Principal Investigator
University of New Mexico
United States: Institutional Review Board
0603C
NCT00250094
May 2004
March 2006
Name | Location |
---|---|
University of New Mexico | Albuquerque, New Mexico 87131 |